vs
辉瑞（PFE）与淡水河谷（VALE）财务数据对比。点击上方公司名可切换其他公司
辉瑞的季度营收约是淡水河谷的2.0倍（$17.6B vs $8.8B），淡水河谷净利率更高（24.3% vs -9.4%，领先33.6%），辉瑞同比增速更快（-1.2% vs -11.3%）
辉瑞是总部位于美国纽约曼哈顿The Spiral的跨国制药及生物技术企业，由德国企业家查尔斯·辉瑞与查尔斯·F·埃尔哈特于1849年在纽约创立，是北美地区历史最悠久的制药企业之一，在全球医药健康领域拥有较高的行业影响力。
淡水河谷是巴西跨国金属矿业集团，也是巴西大型物流运营商之一，为全球最大的铁矿石和镍生产商。其产品线还覆盖锰、铁合金、铜、铝土矿、钾肥、高岭土、钴等，同时运营水电站及铁路、船舶、港口组成的庞大物流网络保障产品运输。
PFE vs VALE — 直观对比
营收规模更大
PFE
是对方的2.0倍
$8.8B
营收增速更快
PFE
高出10.1%
-11.3%
净利率更高
VALE
高出33.6%
-9.4%
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $17.6B | $8.8B |
| 净利润 | $-1.6B | $2.1B |
| 毛利率 | 70.0% | 30.9% |
| 营业利润率 | -9.4% | 22.8% |
| 净利率 | -9.4% | 24.3% |
| 营收同比 | -1.2% | -11.3% |
| 净利润同比 | -501.7% | -22.9% |
| 每股收益（稀释后） | $-0.29 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PFEVALE
| Q4 25 | $17.6B | — | ||
| Q3 25 | $16.7B | — | ||
| Q2 25 | $14.7B | $8.8B | ||
| Q1 25 | $13.7B | — | ||
| Q4 24 | $17.8B | — | ||
| Q3 24 | $17.7B | — | ||
| Q2 24 | $13.3B | $9.9B | ||
| Q1 24 | $14.9B | — |
净利润PFEVALE
| Q4 25 | $-1.6B | — | ||
| Q3 25 | $3.5B | — | ||
| Q2 25 | $2.9B | $2.1B | ||
| Q1 25 | $3.0B | — | ||
| Q4 24 | $410.0M | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $41.0M | $2.8B | ||
| Q1 24 | $3.1B | — |
毛利率PFEVALE
| Q4 25 | 70.0% | — | ||
| Q3 25 | 74.9% | — | ||
| Q2 25 | 74.2% | 30.9% | ||
| Q1 25 | 79.3% | — | ||
| Q4 24 | 66.7% | — | ||
| Q3 24 | 70.3% | — | ||
| Q2 24 | 75.2% | 36.0% | ||
| Q1 24 | 77.3% | — |
营业利润率PFEVALE
| Q4 25 | -9.4% | — | ||
| Q3 25 | 20.0% | — | ||
| Q2 25 | 20.8% | 22.8% | ||
| Q1 25 | 20.3% | — | ||
| Q4 24 | -0.1% | — | ||
| Q3 24 | 26.6% | — | ||
| Q2 24 | -0.8% | 39.1% | ||
| Q1 24 | 23.0% | — |
净利率PFEVALE
| Q4 25 | -9.4% | — | ||
| Q3 25 | 21.3% | — | ||
| Q2 25 | 19.9% | 24.3% | ||
| Q1 25 | 21.6% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | 0.3% | 27.9% | ||
| Q1 24 | 20.9% | — |
每股收益（稀释后）PFEVALE
| Q4 25 | $-0.29 | — | ||
| Q3 25 | $0.62 | — | ||
| Q2 25 | $0.51 | $0.50 | ||
| Q1 25 | $0.52 | — | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.01 | $0.65 | ||
| Q1 24 | $0.55 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $5.5B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $86.5B | $40.5B |
| 总资产 | $208.2B | $90.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PFEVALE
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.6B | $5.5B | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | $6.5B | ||
| Q1 24 | $719.0M | — |
股东权益PFEVALE
| Q4 25 | $86.5B | — | ||
| Q3 25 | $92.8B | — | ||
| Q2 25 | $88.7B | $40.5B | ||
| Q1 25 | $90.3B | — | ||
| Q4 24 | $88.2B | — | ||
| Q3 24 | $92.3B | — | ||
| Q2 24 | $87.7B | $38.4B | ||
| Q1 24 | $92.3B | — |
总资产PFEVALE
| Q4 25 | $208.2B | — | ||
| Q3 25 | $208.7B | — | ||
| Q2 25 | $206.1B | $90.4B | ||
| Q1 25 | $208.0B | — | ||
| Q4 24 | $213.4B | — | ||
| Q3 24 | $219.5B | — | ||
| Q2 24 | $216.2B | $86.6B | ||
| Q1 24 | $221.1B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.3B | — |
| 自由现金流经营现金流 - 资本支出 | $4.5B | — |
| 自由现金流率自由现金流/营收 | 25.6% | — |
| 资本支出强度资本支出/营收 | 4.8% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $9.1B | — |
8季度趋势，按日历期对齐
经营现金流PFEVALE
| Q4 25 | $5.3B | — | ||
| Q3 25 | $4.6B | — | ||
| Q2 25 | $-582.0M | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $6.7B | — | ||
| Q3 24 | $6.7B | — | ||
| Q2 24 | $-1.8B | — | ||
| Q1 24 | $1.1B | — |
自由现金流PFEVALE
| Q4 25 | $4.5B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $-1.2B | — | ||
| Q1 25 | $1.8B | — | ||
| Q4 24 | $5.8B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $-2.4B | — | ||
| Q1 24 | $386.0M | — |
自由现金流率PFEVALE
| Q4 25 | 25.6% | — | ||
| Q3 25 | 24.0% | — | ||
| Q2 25 | -8.2% | — | ||
| Q1 25 | 12.9% | — | ||
| Q4 24 | 32.7% | — | ||
| Q3 24 | 34.3% | — | ||
| Q2 24 | -18.2% | — | ||
| Q1 24 | 2.6% | — |
资本支出强度PFEVALE
| Q4 25 | 4.8% | — | ||
| Q3 25 | 3.6% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 4.8% | — | ||
| Q1 24 | 4.7% | — |
现金转化率PFEVALE
| Q4 25 | — | — | ||
| Q3 25 | 1.30× | — | ||
| Q2 25 | -0.20× | — | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 16.39× | — | ||
| Q3 24 | 1.50× | — | ||
| Q2 24 | -43.44× | — | ||
| Q1 24 | 0.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PFE
| U.S.Commercial Division | $9.0B | 51% |
| Specialty Care | $4.8B | 27% |
| Total Alliance Biopharmaceuticals | $2.6B | 15% |
| Royalty | $480.0M | 3% |
| Pfizer Centre One | $409.0M | 2% |
VALE
暂无分部数据
